Home World News FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma World News FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma By Ogkologos - April 1, 2026 252 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826) Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... April 9, 2025 Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... July 2, 2021 What the Reignited Cancer Moonshot Initiative Means for People With Cancer March 29, 2022 News digest – naked mole-rats, junk food deals, ovarian cancer drug... July 4, 2020 Load more HOT NEWS No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in... The American Society of Clinical Oncology and the American Cancer Society:... ESMO Asia Congress 2022, 2-4 December 2022